TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alterity Therapeutics ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics Limited announced the cessation of Brian Meltzer as a director, effective November 21, 2025. This change in leadership involves Meltzer’s interests in a significant number of securities, including fully paid ordinary shares and various options, which may impact the company’s governance and strategic direction.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is known for its work on innovative treatments aimed at addressing unmet needs in neurological health.
Average Trading Volume: 14,994,693
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.